Seehafer J G, Slupsky J R, Tang S C, Masellis-Smith A, Shaw A R
Department of Medicine, Cross Cancer Institute, Edmonton, Canada.
Biochim Biophys Acta. 1990 Jun 19;1039(2):218-26. doi: 10.1016/0167-4838(90)90189-m.
CD9 is a signal-initiating glycoprotein of uncertain membrane insertion which contains more than one locus of acylation and is distinguished by being the major acylatable platelet protein. The N-terminus of CD9 is blocked to Edman degradation. We investigated whether [3H]myristic acid could be incorporated into CD9, whether that incorporation occurred via an amide linkage, and whether myristate and palmitate were differentially incorporated into the two domains. Pulse-labeling studies, performed on the human osteogenic sarcoma cell line SKOSC which expresses 22 and 24 kDa variants of CD9 demonstrated that the respective precursors of 20.5 and 23 kDa were not radiolabeled by either [3H]myristic acid or [3H]palmitic acid, but that both fatty acids could be ligated to CD9 during the later stages of protein maturation. The failure to incorporate myristic acid cotranslationally suggest that CD9 does not contain amino-terminal amide-bonded myristic acid. Incorporation of radiolabel from both fatty acids proceeded very rapidly and could be visualized after a 10 s pulse. Although myristic acid was partially metabolized into palmitic acid, incorporation of authentic [3H]myristate into CD9 could be demonstrated. The myristic acid bonds were shown to be as sensitive to hydroxylamine treatment as those linking palmitate. Both fatty acids were also incorporated into CD9 in hydroxylamine-sensitive bonds in the presence of cycloheximide, reaching 30-40% of the levels in untreated controls. The sensitivity of myristate ligands to hydroxylamine demonstrates that this fatty acid is not linked via amide, but rather via ester bonds. The sensitivity of [3H]myristate and [3H]palmitate bonds to 2-mercaptoethanol further suggests that either fatty acid is linked via thioester rather than hydroxyester bonds to each domain on CD9. Limited proteolysis analysis with Staphylococcus aureus V8 proteinase of CD9, labeled in the absence or presence of cycloheximide, showed that [3H]myristic acid and [3H]palmitic acid labeled identical peptides, and to the same extent, suggesting that myristate is an alternative substrate for the transacylase(s) involved.
CD9是一种膜插入情况不明的信号起始糖蛋白,它含有不止一个酰化位点,并且是主要的可酰化血小板蛋白。CD9的N端对埃德曼降解法封闭。我们研究了[3H]肉豆蔻酸是否能掺入CD9,这种掺入是否通过酰胺键发生,以及肉豆蔻酸和棕榈酸是否以不同方式掺入两个结构域。对表达22 kDa和24 kDa CD9变体的人骨肉瘤细胞系SKOSC进行的脉冲标记研究表明,20.5 kDa和23 kDa的各自前体都未被[3H]肉豆蔻酸或[3H]棕榈酸放射性标记,但在蛋白质成熟后期,这两种脂肪酸都可与CD9连接。共翻译时未能掺入肉豆蔻酸表明CD9不含有氨基末端酰胺键连接的肉豆蔻酸。来自两种脂肪酸的放射性标记掺入非常迅速,在10秒脉冲后即可观察到。虽然肉豆蔻酸部分代谢为棕榈酸,但可证明真实的[3H]肉豆蔻酸掺入了CD9。肉豆蔻酸键对羟胺处理的敏感性与连接棕榈酸的键相同。在环己酰亚胺存在下,两种脂肪酸也以对羟胺敏感的键掺入CD9,达到未处理对照水平的30 - 40%。肉豆蔻酸配体对羟胺的敏感性表明这种脂肪酸不是通过酰胺键连接,而是通过酯键连接。[3H]肉豆蔻酸和[3H]棕榈酸键对2 - 巯基乙醇的敏感性进一步表明,这两种脂肪酸都是通过硫酯键而非羟基酯键与CD9上的每个结构域连接。用金黄色葡萄球菌V8蛋白酶对在有无环己酰亚胺情况下标记的CD9进行的有限蛋白水解分析表明,[3H]肉豆蔻酸和[3H]棕榈酸标记相同的肽段,且程度相同,这表明肉豆蔻酸是相关转酰基酶的替代底物。